As a CMC leader also supporting marketing at WuXi XDC, I’d like to share this news again which was posted by WuXi XDC’s own new LinkedIn account.
WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.
WuXi XDC and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics (“HySlink”), and CRDMO services spanning from discovery to commercialization.
I’d like to take this opportunity to invite you to follow WuXi XDC’s LinkedIn account right NOW.
#adc #adcs #antibodydrugconjugates #cdmo #crdmo #collaborations #partnership #partnerships
We are excited to announce that WuXi XDC, a leading global CRDMO focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics (“HySlink”), and CRDMO services spanning from discovery to commercialization.
Both parties will synergize their strengths to speed up discovery and development of advanced ADCs by offering the novel T-moiety linker, Exatecan as payload, as well as an integrated discovery and development services. This platformization of new technologies will enable our clients to accelerate selection of an ADC lead at the discovery stage and bring the ADC product quickly from discovery to clinical trials.
Read more: https://lnkd.in/dePH9G6j
#WuXiXDC #CRDMO #ADC #Bioconjugate #Platform #Parntership
